Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

roche laboratories inc. - diazepam (unii: q3jtx2q7tu) (diazepam - unii:q3jtx2q7tu) - diazepam 2 mg - valium is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. in acute alcohol withdrawal, valium may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. valium is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. oral valium may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. the effectiveness of valium in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug for the individual patient. valium is contraindicated in patients with a known hypersensitivity to diazepam and, because of lack of sufficient clinical experience, in pediatric patients under 6 months of age. valium is also contraindicated in patients with myasthenia gravis, severe respiratory insufficiency, severe hepatic insufficiency, and sleep apnea syndrome. it may be used in patients with open-angle glaucoma who are receiving appropriate therapy, but is contraindicated in acute narrow-angle glaucoma. valium contains diazepam, a schedule iv controlled substance. valium is a benzodiazepine and a cns depressant with a potential for abuse and addiction. abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. even taking benzodiazepines as prescribed may put patients at risk for abuse and misuse of their medication. abuse and misuse of benzodiazepines may lead to addiction. abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death. benzodiazepines are often sought by individuals who abuse drugs and other substances, and by individuals with addictive disorders (see warnings: abuse, misuse, and addiction). the following adverse reactions have occurred with benzodiazepine abuse and/or misuse: abdominal pain, amnesia, anorexia, anxiety, aggression, ataxia, blurred vision, confusion, depression, disinhibition, disorientation, dizziness, euphoria, impaired concentration and memory, indigestion, irritability, muscle pain, slurred speech, tremors, and vertigo. the following severe adverse reactions have occurred with benzodiazepine abuse and/or misuse: delirium, paranoia, suicidal ideation and behavior, seizures, coma, breathing difficulty, and death. death is more often associated with polysubstance use (especially benzodiazepines with other cns depressants such as opioids and alcohol). valium may produce physical dependence from continued therapy. physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. abrupt discontinuation or rapid dosage reduction of benzodiazepines or administration of flumazenil, a benzodiazepine antagonist, may precipitate acute withdrawal reactions, including seizures, which can be life-threatening. patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages (i.e., higher and/or more frequent doses), those who have had longer durations of use (see warnings: dependence and withdrawal reactions). to reduce the risk of withdrawal reactions, use a gradual taper to discontinue valium or reduce the dosage (see dosage and administration: discontinuation or dosage reduction of valium and warnings: dependence and withdrawal reactions). acute withdrawal signs and symptoms associated with benzodiazepines have included abnormal involuntary movements, anxiety, blurred vision, depersonalization, depression, derealization, dizziness, fatigue, gastrointestinal adverse reactions (e.g., nausea, vomiting, diarrhea, weight loss, decreased appetite), headache, hyperacusis, hypertension, irritability, insomnia, memory impairment, muscle pain and stiffness, panic attacks, photophobia, restlessness, tachycardia, and tremor. more severe acute withdrawal signs and symptoms, including life-threatening reactions, have included catatonia, convulsions, delirium tremens, depression, hallucinations, mania, psychosis, seizures, and suicidality. protracted withdrawal syndrome associated with benzodiazepines is characterized by anxiety, cognitive impairment, depression, insomnia, formication, motor symptoms (e.g., weakness, tremor, muscle twitches), paresthesia, and tinnitus that persists beyond 4 to 6 weeks after initial benzodiazepine withdrawal. protracted withdrawal symptoms may last weeks to more than 12 months. as a result, there may be difficulty in differentiating withdrawal symptoms from potential re-emergence or continuation of symptoms for which the benzodiazepine was being used. tolerance to valium may develop from continued therapy. tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). tolerance to the therapeutic effect of valium may develop; however, little tolerance develops to the amnestic reactions and other cognitive impairments caused by benzodiazepines.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

richmond pharmaceuticals, inc. - ribavirin (unii: 49717awg6k) (ribavirin - unii:49717awg6k) - ribavirin 200 mg - ribavirin capsules in combination with interferon alfa-2b (pegylated and nonpegylated) is indicated for the treatment of chronic hepatitis c (chc) in patients 3 years of age and older with compensated liver disease [see warnings and precautions (5.9, 5.10) , and use in specific populations (8.4) ]. the following points should be considered when initiating ribavirin combination therapy with peginterferon alfa-2b or interferon alfa-2b: ribavirin combination therapy is contraindicated in: pregnancy category x [see contraindications (4), warnings and precautions (5.1), and nonclinical toxicology (13.1) ]. treatment and posttreatment potential risk to the fetus ribavirin is known to accumulate in intracellular components from where it is cleared very slowly. it is not known whether ribavirin contained in sperm will exert a potential teratogenic effect upon fertilization of the ova. in a study in rats, it was concluded that dominant lethality was not induced by ribavirin at doses up to 200 mg/kg for 5 days (estimat

Ταϊβάν - Κινεζικά - 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

羅氏大藥廠股份有限公司 台北市信義區松仁路100號40樓、40樓之1、41樓之1 (23167467) - trastuzumab - 凍晶注射劑 - trastuzumab (1013000500) mg - trastuzumab - herceptin應使用於下列her2過度表現或her2基因amplification之早期乳癌、轉移性乳癌患者：1.早期乳癌(ebc)：(1)經外科手術、化學療法(術前或術後)之輔助療法。(2)以doxorubicin與cyclophosphamide治療，再合併pactlitaxel或docetaxel之輔助療法。(3)與docetaxel及carboplatin併用之輔助療法。(4)術前與化學療法併用和術後之輔助療法使用於治療局部晚期(包括炎症)乳癌或腫瘤(直徑>2厘米)。2.轉移性乳癌(mbc)：(1)單獨使用於曾接受過一次(含)以上化學療法之轉移性乳癌；除非患者不適合使用anthracyclin或taxane，否則先前之化學治療應至少包括anthracyclin或taxane。使用於荷爾蒙療法失敗之荷爾蒙受體陽性之患者，除非患者不適用荷爾蒙療法。(2)與pactlitaxel或docetaxel併用於未曾接受過化學療法之轉移性乳癌。(3)與芳香環酶抑制劑併用於荷爾蒙受體陽性之轉移性乳癌。3.轉移性胃癌(mgc)：herceptin合併capecitabine(或5-fluorouracil)及cisplatin適用於未曾接受過化學治療之her2過度表現轉移性胃腺癌(或胃食道接合處腺癌)的治療。

Ταϊβάν - Κινεζικά - 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

台灣羅氏醫療診斷設備股份有限公司 台北市中山區民權東路3段2號10樓 (23932173) - trastuzumab - 凍晶注射劑 - trastuzumab (1013000500) mg - trastuzumab - herclon應使用於下列her2過度表現或her2基因amplification之早期乳癌、轉移性乳癌患者說明：1.早期乳癌(ebc)：(1)經外科手術、化學療法(術前或術後)之輔助療法。(2)以doxorubicin與cyclophosphamide治療，再合併pactlitaxel或docetaxel之輔助療法。(3)與docetaxel及carboplatin併用之輔助療法。(4)術前與化學療法併用和術後之輔助療法使用於治療局部晚期(包括炎症)乳癌或腫瘤(直徑>2 厘米)2.轉移性乳癌(mbc)：(1)單獨使用於曾接受過一次(含)以上化學療法之轉移性乳癌；除非患者不適合使用anthracyclin或taxane，否則先前之化學治療應至少包括anthracyclin或taxane。使用於荷爾蒙療法失敗之荷爾蒙受體陽性之患者，除非患者不適用荷爾蒙療法。(2)與pactlitaxel或docetaxel併用於未曾接受過化學療法之轉移性乳癌。(3)與芳香環酶抑制劑併用於荷爾蒙受體陽性之轉移性乳癌。3.轉移性胃癌(mgc)：herclon合併capecitabine(或5-f1uorouracil)及cisplatin適用於未曾接受過化學治療之her2過度表現轉移性胃腺癌(或胃食道接合處腺癌)的治療。

Περού - Ισπανικά - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

roche farma (peru) s.a. - droguerÍa - rituximab - concentrado para solucion para perfusion - 100 mg/10 ml - por - - rituximab

Περού - Ισπανικά - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

roche farma (peru) s.a. - droguerÍa - rituximab - concentrado para solucion para perfusion - 500 mg/50 ml - por vial 50.00 ml - - rituximab

Εκουαδόρ - Ισπανικά - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

f. hoffmann-la roche s.a. [ch] switzerland - dornase alfa 2,50 mg - solucion para inhalaciÓn - cada ampolla con 2,5 ml de solución para inhalación contiene: dornase alfa 2,50 mg

Περού - Ισπανικά - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

roche farma (peru) s.a. - droguerÍa - casirivimab + imdevimab - solucion inyectable y para perfusion - 300mg +300mg - por vial 300.00 mg - - casirivimab y imdevimab

Περού - Ισπανικά - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

roche farma (peru) s.a. - droguerÍa - trastuzumab - polvo para concentrado para solucion para perfusion - 400 mg - por vial 1.00 dosis - - trastuzumab

Περού - Ισπανικά - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

roche farma (peru) s.a. - droguerÍa - casirivimab + imdevimab - solucion inyectable y para perfusion - 120mg/ml + 120mg/ml - por vial 11.10 ml - - casirivimab y imdevimab